P2Y12 inhibitors in acute coronary syndromes: which and when?

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Acute coronary syndromes (ACS) are a leading cause of death and hospitalization, primarily driven by plaque rupture and platelet activation.
• Antiplatelet therapy, particularly dual antiplatelet therapy (DAPT) with aspirin, is fundamental in managing ACS.
• Platelet P2Y12 receptor inhibitors are a critical component of DAPT, offering various mechanisms and clinical profiles.

Purpose of the Study:

• To review the properties and clinical profiles of P2Y12 receptor inhibitors.
• To discuss the role of newer P2Y12 inhibitors in the management of ACS.
• To compare the efficacy and safety of different P2Y12 inhibitors.

Main Methods:

• Review of existing literature on P2Y12 receptor inhibitors, including data from large phase 3 clinical trials.
• Comparison of irreversible (thienopyridines: clopidogrel, prasugrel) and reversible (non-thienopyridines: ticagrelor, elinogrel) P2Y12 inhibitors.
• Analysis of antiplatelet effect, genetic variability impact (CYP2C19), and clinical outcomes (cardiovascular events, bleeding).

Main Results:

• Newer P2Y12 inhibitors (ticagrelor, prasugrel) demonstrate more uniform and complete antiplatelet effects than clopidogrel.
• These agents are less affected by CYP2C19 genetic variability, leading to more predictable efficacy.
• Phase 3 trials show ticagrelor and prasugrel reduce major cardiovascular events in ACS compared to clopidogrel, albeit with a slight increase in bleeding.

Conclusions:

• P2Y12 receptor inhibitors are essential in ACS management when combined with aspirin.
• Newer agents offer improved efficacy in reducing cardiovascular events compared to clopidogrel.
• The choice of P2Y12 inhibitor should consider the balance between efficacy and bleeding risk in individual patients.